N-Glycoproteomics of PDX Models
Patient-derived xenograft (PDX) models are the future of personalized cancer therapy. Professional researchers of CD BioGlyco are dedicated to N-glycoproteomics analysis in PDX models, providing scientific help to our clients in developing tumor and cancer therapies. We look forward to being your competent research assistant in your glycoproteomics research.
Advantage of PDX models
PDX provides the most translational preclinical model for efficacy screening in cancer drug development. PDX models have the characteristic of being derived directly from patient tumors, and they can generate samples that are authentic to the host tumor. Their ability to accurately replicate tumor growth, tumor cells diversity, and tumor progression including metastatic potential reflect the heterogeneity and diversity of the human patient population.
Proteins of the cell membrane and extracellular matrix are usually N-glycosylated and can be secreted or shed into the extracellular environment. Therefore, N-glycopeptide-based enrichment can be a useful strategy for detecting tissue leakage proteins in serum. Recently, a workflow using clinically relevant PDX and N-glycopeptide enrichment was developed, which can easily identify "human-unique" proteins in mouse serum backgrounds, thus overcoming the limitations relevant to proteomics-based biomarker discovery. This strategy allowed researchers to identify potentially novel tumor-associated proteins.
Our Services
CD BioGlyco has systematically developed various targeted glycoproteomics techniques such as parallel reaction monitoring mass spectrometry (PRM-MS) for the quantification of tumor-associated peptides and analysis of N-glycoproteomics in patient serum. We provide our clients with the following services, but are not limited to:
- Global N-glycoproteome analysis: Our company provides comprehensive identification and quantification services of all N-glycosylated proteins and their corresponding glycosylation sites in PDX samples.
- Site-specific N-glycosylation analysis: We provide detailed characterization of N-glycan structures present at specific glycosylation sites of target proteins, such as high-resolution site heterogeneity analysis.
- Quantitative N-glycoproteomics: Through label-free or labeled quantification strategies, our researchers provide comparative analysis of N-glycoproteome profiles in different PDX models or at different stages of progression.
- Advanced informatics analysis: We use specialized bioinformatics processes and glycoinformatics software for data processing, spectral resolution, glycopeptide identification, and quantitative analysis. This includes algorithms for ab initio sequencing of glycans and glycosylation site characterization.
Workflow
Applications
- Our service can be used to discover aberrant N-glycosylation patterns on cell surfaces or secreted proteins, and can also be used as a new target for the development of antibody-drug conjugates.
- Our service can be used to study changes in N-glycosylation profiles in drug-resistant PDX models, providing insights into resistance mechanisms.
- Our services can be used for novel N-glycoprotein biomarkers for early detection of specific cancer types, prognosis, or prediction of treatment response.
Advantages of Us
- Our team combines extensive knowledge in complex carbohydrate analysis with a profound understanding of cancer biology and PDX models, ensuring highly relevant and impactful results.
- We utilize a seamless integration of advanced MS, sophisticated enrichment techniques, and cutting-edge bioinformatics tools, providing unparalleled depth and accuracy in glycoproteomic analysis.
- Our optimized workflows are designed to maximize the identification of N-glycopeptides, including those present at low abundance, ensuring comprehensive coverage of the N-glycoproteome in complex PDX samples.
Publication Data
Technology: Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
Journal: Scientific Reports
Published: 2019
IF: 3.8
Results: By studying urinary proteomic changes in a PDX nude mouse model, researchers have found that nude mice with transplanted colorectal tumors have detectable human-derived peptides in their urine in a well-defined manner. This suggests that tumor-secreted proteins enter the urine, but unlike the immunocompetent rat model, nude mice did not detect host immune response-related proteins in their urine due to immunodeficiency.
Fig.1 SDS-PAGE analysis of nude mouse urinary proteins. (Liu, et al., 2019)
Frequently Asked Questions
By leveraging the wealth of information we have on multiple tumor models, CD BioGlyco has the capacity to assist clients in the N-glycoproteomics analysis of PDX models. Our professional scientific services and efficient technical support will accelerate your research related to glycoproteomics. If you need our technical assistance, please feel free to contact us and we will respond as soon as possible.
Associated Services
CD BioGlyco offers a range of complementary services that enhance your research utilizing N-glycoproteomics of PDX models:
- Relative Quantification of Glycoprotein
- Absolute Quantification of Glycoprotein
- N-Glycosylation Site Occupation
- Targeted glycoprotein analysis: Focused quantitative analysis of specific N-glycoproteins of interest
- Glycan Array Screening: To investigate the binding specificities of your proteins or antibodies to a wide range of glycan structures.
Reference
- Liu, Y.; et al. Changes in the urinary proteome in a patient-derived xenograft (PDX) nude mouse model of colorectal tumor. Scientific Reports. 2019, 9(1): 4975. (Open Access)
